PriceTargets.com logo

CorMedix - CRMD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.86
  • Forecasted Upside: 104.34%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 2 Strong Buy Ratings
$7.76 As of 01/30/2026 05:00 PM ET
▼ -0.26 (-3.24%)

This chart shows the closing price for CRMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CorMedix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRMD

Analyst Price Target is $15.86
▲ +104.34% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for CorMedix in the last 3 months. The average price target is $15.86, with a high forecast of $22.00 and a low forecast of $13.00. The average price target represents a 104.34% upside from the last price of $7.76.

This chart shows the closing price for CRMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in CorMedix. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/10/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/8/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/6/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2025
  • 3 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2026
  • 2 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2026

Latest Recommendations

  • 2 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/23/2026HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $13.00
1/21/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
1/21/2026Royal Bank Of CanadaSet TargetOutperform ➝ Outperform$22.00 ➝ $13.00
1/12/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
1/8/2026Truist FinancialSet Target$16.00
1/8/2026Needham & Company LLCLower TargetBuy ➝ Buy$16.00 ➝ $15.00
1/8/2026D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
12/18/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
11/13/2025HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
11/12/2025Needham & Company LLCLower TargetBuy ➝ Buy$20.00 ➝ $16.00
11/12/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$14.00
11/4/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
10/21/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$21.00 ➝ $22.00
10/20/2025D Boral CapitalUpgradeHold ➝ Strong-Buy
10/20/2025D. Boral CapitalUpgradeHold ➝ Buy$14.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/6/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/9/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$22.00
8/8/2025HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $17.00
6/30/2025D Boral CapitalDowngradeStrong-Buy ➝ Hold
6/30/2025D. Boral CapitalDowngradeBuy ➝ Hold
6/30/2025HC WainwrightInitiated CoverageBuy$20.00
6/24/2025Needham & Company LLCBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
6/23/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00
6/20/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.00
5/7/2025Needham & Company LLCBoost TargetBuy ➝ Buy$12.00 ➝ $15.00
5/6/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00
3/26/2025Needham & Company LLCLower TargetBuy ➝ Buy$18.00 ➝ $12.00
3/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/7/2025Leerink PartnersUpgradeStrong-Buy
3/7/2025Leerink PartnersInitiated CoverageOutperform$18.00
3/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
1/22/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
1/13/2025D. Boral CapitalInitiated CoverageBuy$15.00
12/19/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$11.00 ➝ $12.00
10/31/2024Needham & Company LLCBoost TargetBuy ➝ Buy$10.00 ➝ $18.00
10/22/2024Truist FinancialBoost TargetBuy ➝ Buy$12.00 ➝ $17.00
8/26/2024Rodman & RenshawInitiated CoverageBuy$13.00
8/15/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$9.00 ➝ $9.00
8/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
7/25/2024Truist FinancialLower TargetBuy ➝ Buy$14.00 ➝ $12.00
6/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
4/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$19.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$10.00
3/13/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$10.00 ➝ $9.00
1/31/2024Truist FinancialLower TargetBuy ➝ Buy$18.00 ➝ $14.00
11/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$18.00
11/15/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$6.00 ➝ $10.00
11/15/2023Needham & Company LLCLower TargetBuy ➝ Buy$12.00 ➝ $10.00
11/15/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$19.00
8/10/2023Royal Bank Of CanadaInitiated CoverageOutperform$6.00
8/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$13.00 ➝ $12.00
5/19/2023JMP SecuritiesBoost Target$16.00 ➝ $19.00
3/31/2023Needham & Company LLCReiterated RatingBuy$13.00
3/31/2023JMP SecuritiesReiterated RatingMarket Outperform$16.00
3/3/2023Needham & Company LLCReiterated RatingBuy$13.00
3/1/2023JMP SecuritiesBoost TargetMarket Perform$14.00 ➝ $16.00
11/11/2022Needham & Company LLCBoost TargetBuy$12.00 ➝ $13.00
8/12/2022Truist FinancialLower TargetBuy$27.00 ➝ $16.00
8/9/2022Needham & Company LLCLower Target$20.00 ➝ $12.00
8/9/2022JMP SecuritiesLower TargetMarket Outperform$19.00 ➝ $14.00
3/30/2022JMP SecuritiesReiterated RatingBuy$19.00
3/18/2022JMP SecuritiesReiterated RatingBuy$19.00
10/21/2021JMP SecuritiesReiterated RatingBuy$19.00
10/5/2021JMP SecuritiesReiterated RatingBuy$19.00
8/24/2021JMP SecuritiesReiterated RatingBuy$22.00
5/14/2021Needham & Company LLCLower TargetBuy$31.00 ➝ $29.00
3/31/2021Truist FinancialLower Target$30.00 ➝ $27.00
3/2/2021B. RileyReiterated RatingBuy$25.00 ➝ $13.50
2/17/2021Needham & Company LLCInitiated CoverageBuy$31.00
2/9/2021B. RileyBoost Target$11.00 ➝ $25.00
(Data available from 2/1/2021 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 29 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2025
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2025
  • 11 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2025
  • 22 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2025
  • 10 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2025
  • 15 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2025
  • 13 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2026
  • 10 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2026

Current Sentiment

  • 10 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

CorMedix logo
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Read More

Today's Range

Now: $7.76
Low: $7.66
High: $8.15

50 Day Range

MA: $9.93
Low: $6.78
High: $12.73

52 Week Range

Now: $7.76
Low: $5.60
High: $17.43

Volume

2,353,169 shs

Average Volume

4,073,853 shs

Market Capitalization

$611.40 million

P/E Ratio

3.77

Dividend Yield

N/A

Beta

1.36

Frequently Asked Questions

What sell-side analysts currently cover shares of CorMedix?

The following equities research analysts have issued stock ratings on CorMedix in the last twelve months: D Boral Capital, D. Boral Capital, HC Wainwright, JMP Securities, Leerink Partners, Needham & Company LLC, Royal Bank Of Canada, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for CRMD.

What is the current price target for CorMedix?

0 Wall Street analysts have set twelve-month price targets for CorMedix in the last year. Their average twelve-month price target is $15.86, suggesting a possible upside of 104.3%. JMP Securities has the highest price target set, predicting CRMD will reach $22.00 in the next twelve months. Royal Bank Of Canada has the lowest price target set, forecasting a price of $13.00 for CorMedix in the next year.
View the latest price targets for CRMD.

What is the current consensus analyst rating for CorMedix?

CorMedix currently has 2 hold ratings, 5 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRMD will outperform the market and that investors should add to their positions of CorMedix.
View the latest ratings for CRMD.

What other companies compete with CorMedix?

Other companies that are similar to CorMedix include Arcus Biosciences, Mesoblast, Sarepta Therapeutics, Ascentage Pharma Group International and Recursion Pharmaceuticals. Learn More about companies similar to CorMedix.

How do I contact CorMedix's investor relations team?

CorMedix's physical mailing address is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. The company's listed phone number is (908) 517-9500 and its investor relations email address is [email protected]. The official website for CorMedix is www.cormedix.com. Learn More about contacing CorMedix investor relations.